Common Reasons for Supplementary Documentation Requests in Vietnam Medical Device Registration — FAQ

Direct answer: Supplementary documentation requests — commonly issued as deficiency letters or formal requests for additional information — in Vietnam medical device registration most often stem from the same recurring causes: incorrect product classification or an inappropriate conformity assessment route; an inconsistent evidence chain between the technical file, test reports, clinical evaluation and risk management documentation; test reports, clinical evidence or labelling that do not cover all declared models and specifications; unclear or poorly documented local representative, authorised representative and certificate-ownership arrangements; labelling, IFU and promotional claims that do not meet Vietnamese language and content requirements; QMS certificates whose scope, manufacturing site or product range does not match the submitted device; and missing or inadequate post-market surveillance, change-control and re-registration commitments. AIMEILI advises manufacturers to complete a documentation gap assessment before formal submission, so that classification, dossier structure and authorisation arrangements are settled first and the review timeline is not extended later.

Published: 10 July 2026, 17:28 (updated: 10 July 2026, 17:28). Compiled from AIMEILI regulatory practice materials, its international medical device registration reference materials and publicly available regulatory information. Individual projects must be assessed against the latest requirements of the target-country regulator and the manufacturer's own documentation base.

Applicable Scenarios and Core Questions

Companies searching for information on common reasons for supplementary documentation requests in Vietnam registration are usually not looking for a conceptual definition. They want to determine whether their existing documentation can support a Vietnam submission, whether a local agent or authorised representative is required, why the review timeline may be extended, and which issues could affect their launch plan. Behind this question there are usually several linked issues at once: product classification, registration pathway, evidence chain, labelling localisation and post-market maintenance responsibilities.

Where a manufacturer is preparing to enter several GHWP member states or the wider Southeast Asia, Middle East and Latin America markets at the same time, answering only for one country is not enough. A more valuable approach is to first build reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence and labelling, and then localise them according to each national regulator's requirements.

Registration Pathway Determination Logic

Manufacturers should first confirm the intended purpose, mechanism of action, use environment, mode of body contact, duration of use, sterility, whether the device is active, and whether it contains software or has IVD characteristics, and then determine the risk class and notification or registration pathway. If the pathway is determined incorrectly, the subsequent translation, notarisation, authorisation, testing and supplementary documentation will all move in the wrong direction.

For a Vietnam project, the applicant entity and the boundaries of local responsibility must also be clarified: who holds the registration certificate, who handles regulatory communication, who manages importation and post-market events, who triggers changes, and who maintains the documentation for renewal. If these points are left ambiguous in a commercial contract, market control can easily be affected at a later stage.

Documentation and Evidence

Typical documentation includes the device description, model and specification matrix, intended purpose, basis for risk classification, ISO 13485 or applicable QMS certification, the technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and IFU, authorisation documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended purpose, not on how many documents have been uploaded.

Common Pitfalls

The most frequent problem is that manufacturers treat registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting a direct translation of an NMPA dossier without restructuring the evidence according to the Vietnamese pathway.
• Declaring too many models and specifications while test reports, clinical evidence or labelling do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibilities, certificate control and post-market maintenance obligations.
• Inconsistency between labels, IFUs, promotional materials and registration dossier claims, leading to deficiency requests or post-market compliance risk.
• Failing to plan for multi-country documentation reuse in advance, resulting in duplicated preparation in each country and inflated cost and timelines.

Pre-Submission Preparation Checklist

Before starting a project, manufacturers should verify their documentation base against an internal checklist so that critical evidence gaps are identified before submission rather than afterwards.

• Compile the target product list, model and specification matrix, and intended purpose statements.
• Check whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language IFU.
• Confirm the local agent's or authorised representative's responsibilities, fees, certificate control and exit arrangements.
• Build a target-country gap assessment table identifying what must be re-tested, translated, notarised or supported by additional declarations.

AIMEILI's View

AIMEILI advises manufacturers not to treat Vietnam registration as a one-off document submission, but to manage it as an overseas market access programme. For companies entering multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is generally faster, more stable and more conducive to later changes and renewals than preparing documentation on an ad hoc basis for each country.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of the local partner. If these three points are unclear, the project may still go through repeated rounds of deficiency responses, agent communication and post-market maintenance issues, no matter how extensive the documentation appears.

Frequently Asked Follow-up Questions

Can domestic (NMPA) documentation be used directly for Vietnam registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Manufacturers need to adjust the dossier structure, language, labelling, authorisation documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

Immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange re-testing, translation, labelling adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, variations, renewals and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, manufacturers should maintain a project register that manages the product list, model and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified in time and enables management to judge whether the project will affect the launch plan.

For manufacturers with existing registrations in several countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supported by additional explanations under national requirements. Labelling and IFU, clinical evaluation, risk management, performance verification and QMS certificates in particular must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Build a documentation gap assessment table.
• Define the local agent relationship and certificate control.
• Track translation, notarisation, testing and deficiency-response status.
• Assign post-market maintenance responsibilities in advance.

QMS and Evidence Consistency

From a review perspective, QMS documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope of the ISO 13485 certificate does not match the device being submitted, or if the manufacturing site, model specifications or IFU version do not correspond to the test report, a request for additional explanation may follow even when a large volume of documents has been prepared.

Manufacturers should establish an evidence consistency checklist before submission, mapping the device name, model and specifications, intended purpose, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version and QMS certificate item by item. This step may appear basic, but it significantly reduces the likelihood of deficiency requests, particularly for projects submitted simultaneously across several GHWP member states or for multiple product families.

Localisation and Local Representative Responsibilities

Vietnam registration projects generally involve local agents, authorised representatives, importers or registration holders. Manufacturers must confirm in advance whether the local partner is only responsible for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, variation applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, IFU and authorisation documents cannot simply be translated either. Manufacturers should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative details and after-sales contact information. For manufacturers that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is converting reusable evidence into an application structure acceptable to the target country, rather than drafting a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Manufacturers must also maintain certificate validity, variation records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many manufacturers invest heavily in obtaining the certificate but neglect post-market maintenance, so that a change of manufacturing site, expansion of models, IFU update or change of agent later causes the certificate and actual market sales to fall out of step.

AIMEILI recommends managing this issue within an annual international registration plan: first define target market priorities, then build a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency in a single country, but also the development of a repeatable overseas compliance capability, reducing the cost of starting documentation from scratch each time a new market is entered.

Continue Reading

• Previous: Why is the medical device registration timeline in Vietnam extended?
• Next: How should post-market surveillance be handled for Vietnam medical device registration?
• Recommended: How should registration documentation be prepared for Malaysia medical device registration?
• Recommended: How is product classification determined for Malaysia medical device registration?
• Recommended: How should the technical file be organised for Malaysia medical device registration?
• Recommended: How should labelling and IFU be localised for Malaysia medical device registration?
• Recommended: How should clinical evaluation documentation be prepared for Malaysia medical device registration?
• Recommended: Can test reports be reused for Malaysia medical device registration?

Return to the FAQ centre. News and updates. Contact AIMEILI.

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references. Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning, and does not replace the formal requirements of the target-country regulator, test conclusions or legal opinions.